Lu Q - Search Results

1

Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy.

Xia X, Yang Z, Lu Q, Liu Z, Wang L, Du J, Li Y, Yang DH, Wu S. Xia X, et al. Among authors: lu q. Mol Cancer. 2024 Aug 26;23(1):175. doi: 10.1186/s12943-024-02079-8. Mol Cancer. 2024. PMID: 39187850 Free PMC article. Review.

2

Reprogramming the tumor microenvironment by genome editing for precision cancer therapy.

Liu K, Cui JJ, Zhan Y, Ouyang QY, Lu QS, Yang DH, Li XP, Yin JY. Liu K, et al. Mol Cancer. 2022 Apr 11;21(1):98. doi: 10.1186/s12943-022-01561-5. Mol Cancer. 2022. PMID: 35410257 Free PMC article. Review.

3

METTL3 regulates M6A methylation-modified EBV-pri-miR-BART3-3p to promote NK/T cell lymphoma growth.

Wu S, Wang H, Yang Q, Liu Z, Du J, Wang L, Chen S, Lu Q, Yang DH. Wu S, et al. Among authors: lu q. Cancer Lett. 2024 Aug 10;597:217058. doi: 10.1016/j.canlet.2024.217058. Epub 2024 Jun 14. Cancer Lett. 2024. PMID: 38880226

4

Editorial: RNA and RNA modification in the pathogenesis, diagnosis and treatment of cancers, Volume II.

Lu Q, Wang L, Zhang JY, Yang DH. Lu Q, et al. Front Oncol. 2023 Mar 10;13:1164399. doi: 10.3389/fonc.2023.1164399. eCollection 2023. Front Oncol. 2023. PMID: 36968996 Free PMC article. No abstract available.

5

Editorial: ABC transporters and drug resistance.

Lu Q, Ambudkar SV, Yang DH. Lu Q, et al. Drug Resist Updat. 2024 Nov;77:101135. doi: 10.1016/j.drup.2024.101135. Epub 2024 Aug 10. Drug Resist Updat. 2024. PMID: 39178712 No abstract available.

6

Pacritinib for myelofibrosis in adults with thrombocytopenia.

Yang DH, Lu Q, Zhu Z, Huang G, Young K. Yang DH, et al. Among authors: lu q. Drugs Today (Barc). 2022 Dec;58(12):577-589. doi: 10.1358/dot.2022.58.12.3474538. Drugs Today (Barc). 2022. PMID: 36651066 Review.

7

The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.

Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, Lu QS, Singh S, Yang DH, Talele TT, Ambudkar SV, Chen ZS. Ding PR, et al. PLoS One. 2011 Apr 28;6(4):e19329. doi: 10.1371/journal.pone.0019329. PLoS One. 2011. PMID: 21552528 Free PMC article.

8

RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cells.

Dong XD, Lu Q, Li YD, Cai CY, Teng QX, Lei ZN, Wei ZH, Yin F, Zeng L, Chen ZS. Dong XD, et al. Among authors: lu q. J Transl Int Med. 2024 Jul 27;12(3):288-298. doi: 10.2478/jtim-2024-0011. eCollection 2024 Jun. J Transl Int Med. 2024. PMID: 39081282 Free PMC article.

9

The predictive value of pan-immune inflammatory index for early recurrence of atrial fibrillation after cryoablation.

Gu P, Xu P, Chen Y, Li J, Sun H, Xu H, Lu Q. Gu P, et al. Among authors: lu q. BMC Cardiovasc Disord. 2024 Nov 23;24(1):669. doi: 10.1186/s12872-024-04329-5. BMC Cardiovasc Disord. 2024. PMID: 39580428 Free article.

10

The importance of developing reproducible primary endpoints for clinical trials in systemic lupus erythematosus.

Yang B, Chen Y, Jiang J, Chang C, Wu H, Gershwin ME, Lu Q. Yang B, et al. Among authors: lu q. Clin Rheumatol. 2024 Nov 23. doi: 10.1007/s10067-024-07236-4. Online ahead of print. Clin Rheumatol. 2024. PMID: 39579266

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,189 results

Search Page

Filters